290 related articles for article (PubMed ID: 17473456)
21. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
[TBL] [Abstract][Full Text] [Related]
22. In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats - A Pilot Study.
Bera R; Kundu A; Sen T; Adhikari D; Karmakar S
Planta Med; 2016 Apr; 82(6):544-50. PubMed ID: 26916641
[TBL] [Abstract][Full Text] [Related]
23. In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis.
Mukkavilli R; Pinjari J; Patel B; Sengottuvelan S; Mondal S; Gadekar A; Verma M; Patel J; Pothuri L; Chandrashekar G; Koiram P; Harisudhan T; Moinuddin A; Launay D; Vachharajani N; Ramanathan V; Martin D
Eur J Pharm Sci; 2014 Dec; 65():147-55. PubMed ID: 25261338
[TBL] [Abstract][Full Text] [Related]
24. Investigation of
K Pinjari MJS; Somani R; Gilhotra RM
Indian J Pharmacol; 2017; 49(4):297-303. PubMed ID: 29326490
[TBL] [Abstract][Full Text] [Related]
25. Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Basavapathruni A; Olhava EJ; Daigle SR; Therkelsen CA; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Dovletoglou A; Richon VM; Pollock RM; Copeland RA; Moyer MP; Chesworth R; Pearson PG; Waters NJ
Biopharm Drug Dispos; 2014 May; 35(4):237-52. PubMed ID: 24415392
[TBL] [Abstract][Full Text] [Related]
26. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
[TBL] [Abstract][Full Text] [Related]
27. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
Obermeier M; Yao M; Khanna A; Koplowitz B; Zhu M; Li W; Komoroski B; Kasichayanula S; Discenza L; Washburn W; Meng W; Ellsworth BA; Whaley JM; Humphreys WG
Drug Metab Dispos; 2010 Mar; 38(3):405-14. PubMed ID: 19996149
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
[TBL] [Abstract][Full Text] [Related]
29. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
[TBL] [Abstract][Full Text] [Related]
30. Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats.
Zainuddin M; Vinod AB; Gurav SD; Police A; Kumar A; Mithra C; Dewang P; Kethiri RR; Mullangi R
Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):1-7. PubMed ID: 25297456
[TBL] [Abstract][Full Text] [Related]
31. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
[TBL] [Abstract][Full Text] [Related]
32. Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.
Patel H; Modi N; Chaudhari J; Patel P; Giri P; Patel H; Pandya V; Desai R; Jain M
Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):725-740. PubMed ID: 35881329
[TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
34. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and metabolism of 4-O-methylhonokiol in rats.
Yu HE; Oh SJ; Ryu JK; Kang JS; Hong JT; Jung JK; Han SB; Seo SY; Kim YH; Park SK; Kim HM; Lee K
Phytother Res; 2014 Apr; 28(4):568-78. PubMed ID: 23824979
[TBL] [Abstract][Full Text] [Related]
36. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.
Ahn S; Kearbey JD; Li CM; Duke CB; Miller DD; Dalton JT
Drug Metab Dispos; 2011 Apr; 39(4):636-43. PubMed ID: 21233217
[TBL] [Abstract][Full Text] [Related]
37. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
Wang H; Yu N; Chen D; Lee KC; Lye PL; Chang JW; Deng W; Ng MC; Lu T; Khoo ML; Poulsen A; Sangthongpitag K; Wu X; Hu C; Goh KC; Wang X; Fang L; Goh KL; Khng HH; Goh SK; Yeo P; Liu X; Bonday Z; Wood JM; Dymock BW; Kantharaj E; Sun ET
J Med Chem; 2011 Jul; 54(13):4694-720. PubMed ID: 21634430
[TBL] [Abstract][Full Text] [Related]
38. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species.
Kalgutkar AS; Choo E; Taylor TJ; Marfat A
Xenobiotica; 2004 Aug; 34(8):755-70. PubMed ID: 15690763
[TBL] [Abstract][Full Text] [Related]
39. Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man.
Allan G; Davis J; Dickins M; Gardner I; Jenkins T; Jones H; Webster R; Westgate H
Xenobiotica; 2008 Jun; 38(6):620-40. PubMed ID: 18570162
[TBL] [Abstract][Full Text] [Related]
40. In vitro-in vivo correlation and translation to the clinical outcome for CJ-13,610, a novel inhibitor of 5-lipoxygenase.
Matthew Hutzler J; Linder CD; Melton RJ; Vincent J; Daniels JS
Drug Metab Dispos; 2010 Jul; 38(7):1113-21. PubMed ID: 20375180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
